The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
Open accessAbstract
There is considerable evidence that the potent vasoconstrictor endothelin‐1 (ET‐1) contributes to the pathogenesis of a variety of cardiovascular diseases. As such, pharmacological manipulation of the ET system might represent a promising therapeutic goal. Many clinical trials have assessed the potential of ET receptor antagonists in cardiovascular disease, the most positive of which have resulted in the licensing of the mixed ET receptor antagonist bosentan, and the selective ET A receptor antagonists, sitaxsentan and ambrisentan, for the treatment of pulmonary arterial hypertension (PAH). In contrast, despite encouraging data from in vitro and animal studies, outcomes in human heart failure have been disappointing, perhaps illustrating the risk of extrapolating preclinical work to man. Many further potential applications of these compounds, including resistant hypertension, chronic kidney disease, connective tissue disease and sub‐arachnoid haemorrhage are currently being investigated in the clinic. Furthermore, experience from previous studies should enable improved trial design and scope remains for development of improved compounds and alternative therapeutic strategies. Although ET‐converting enzyme inhibitors may represent one such alternative, there have been relatively few suitable compounds developed, and consequently, clinical experience with these agents remains extremely limited. Recent advances, together with an increased understanding of the biology of the ET system provided by improved experimental tools (including cell‐specific transgenic deletion of ET receptors), should allow further targeting of clinical trials to diseases in which ET is involved and allow the therapeutic potential for targeting the ET system in cardiovascular disease to be fully realized. British Journal of Pharmacology(2008)153, 1105–1119; doi:10.1038/sj.bjp.0707516; published online 29 October 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Fattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
Amiri, F., Virdis, A., Neves, M. F., Iglarz, M., Seidah, N. G., Touyz, R. M., Reudelhuber, T. L., & Schiffrin, E. L. (2004) · Circulation · doi:10.1161/01.cir.0000144462.08345.b9 · Cited by 346 · cited 1×
“Furthermore, EC-specific ET-1 overexpres- sing mice are not hypertensive (Amiri et al., 2004), suggesting that actions of ET-1 beyond vasoconstriction, possibly including upregulation of ETB receptor-mediated vasodilata- tion and natriuretic pathways, can provide protection against physiological…”
Background
Cited by
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
“…ET-1 (Yanagisawa et al. 1988, Yanagisawa & Masaki 1989, Schini & Vanhoutte 1991b, Vanhoutte 1993, Rubanyi & Polokoff 1994, B€ohm & Pernow 2007, Kirkby et al. 2008; see section Endothelin-1) and other non-prostanoid vasoconstrictor substances (Cosentino et al. 1994, Dhein et al. 1997,…”
BackgroundBernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Endothelial dysfunction and vascular disease
Vanhoutte, P. M., Shimokawa, H., Tang, E. H. C., & Feletou, M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01964.x · Cited by 806
Vollmar, B., & Menger, M. D. (2009) · Physiological Reviews · doi:10.1152/physrev.00027.2008 · Cited by 500
Regulation of Blood Pressure and Salt Homeostasis by Endothelin
Kohan, D. E., Rossi, N. F., Inscho, E. W., & Pollock, D. M. (2011) · Physiological Reviews · doi:10.1152/physrev.00060.2009 · Cited by 433
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
Hoeper, M. M., Barberà, J. A., Channick, R. N., Hassoun, P. M., Lang, I. M., Manes, A., Martinez, F. J., Naeije, R., Olschewski, H., Pepke-Zaba, J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.008 · Cited by 399
Barton, M., & Yanagisawa, M. (2008) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y08-059 · Cited by 305
Role of the endothelin axis and its antagonists in the treatment of cancer
Bagnato, A., Loizidou, M., Pflug, B., Curwen, J., & Growcott, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01217.x · Cited by 107
Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort
Fedorowski, A., Burri, P., Struck, J., Juul‐Möller, S., & Melander, O. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12043 · Cited by 62
Metadata
- Authors
- Kirkby, N. S., Hadoke, P. W. F., Bagnall, A. J., & Webb, D. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-03
- Volume
- 153
- Issue
- 6
- Pages
- 1105-1119
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2105356761
- Cited by
- 176
- References
- 3
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.